Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study
Loredana Amoroso, Giovanni Erminio, Guy Makin, Andrew D. J. Pearson, Penelope Brock, Dominique Valteau-Couanet, Victoria Castel, Marlène Pasquet, Genevieve Laureys, Caroline Thomas, Roberto Luksch, Ruth Ladenstein, Riccardo Haupt, Alberto Garaventa,
Cancer Res Treat. 2018;50(1):148-155.   Published online 2017 Mar 21     DOI: https://doi.org/10.4143/crt.2016.511
Citations to this article as recorded by Crossref logo
Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience
P. Berlanga, C. Pasqualini, U. Pötschger, C. Sangüesa, M.R. Castellani, A. Cañete, R. Luksch, M. Elliot, G. Schreier, M. Kropf, D. Morgenstern, V. Papadakis, S. Ash, E. Ruud, P. Brock, A. Wieczorek, P. Kogner, T. Trahair, P. Ambros, T. Boterberg, V. Caste
European Journal of Cancer.2021; 144: 1.     CrossRef
Survival in patients with high-risk neuroblastoma treated without autologous stem cell transplant or dinutuximab beta
Richa Jain, Amita Trehan, Prema Menon, Rakesh Kapoor, Nandita Kakkar, Srinivasan Radhika, Akshay Kumar Saxena, Bhagwant Rai Mittal, Neelam Varma, Ram Samujh, Deepak Bansal
Pediatric Hematology and Oncology.2021; 38(4): 291.     CrossRef
Neuroblastoma
Christine Chung, Tom Boterberg, John Lucas, Joseph Panoff, Dominique Valteau‐Couanet, Barbara Hero, Rochelle Bagatell, Christine E. Hill‐Kayser
Pediatric Blood & Cancer.2021;[Epub]     CrossRef
Effect of high-dose chemotherapy plus stem cell rescue on the survival of patients with neuroblastoma modified by MYCN gene gain/amplification and remission status: a nationwide registration study in Japan
Yuya Saito, Mitsuyoshi Urashima, Yoshiyuki Takahashi, Atsushi Ogawa, Chikako Kiyotani, Yuki Yuza, Katsuyoshi Koh, Kenichiro Watanabe, Yoshiyuki Kosaka, Hiroaki Goto, Atsushi Kikuta, Keiko Okada, Yuhki Koga, Junya Fujimura, Masami Inoue, Atsushi Sato, Yosh
Bone Marrow Transplantation.2021;[Epub]     CrossRef
Connectivity Map Analysis Indicates PI3K/Akt/mTOR Inhibitors as Potential Anti-Hypoxia Drugs in Neuroblastoma
Paolo Uva, Maria Carla Bosco, Alessandra Eva, Massimo Conte, Alberto Garaventa, Loredana Amoroso, Davide Cangelosi
Cancers.2021; 13(11): 2809.     CrossRef
Off-label drug use in paediatric haemato-oncology patients: financial implications and proposed solutions for Belgian patients
T. Bauters, D. Heenen, K. Norga, A. Van Damme, A. Uyttebroeck, G. Laureys
European Journal of Pediatrics.2021;[Epub]     CrossRef
Early Use of Dinutuximab Beta in Patients with High-Risk Neuroblastoma
Neofit Spasov, Mariya Spasova, Stella Stabouli
Case Reports in Pediatrics.2021; 2021: 1.     CrossRef
Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study
Alberto Garaventa, Ulrike Poetschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Martin Elliott, Shifra Ash, Godfrey C. F. Chan, Geneviève Laureys, Maja Beck-Popovic, Kim Vettenranta, Walentyna Balwierz, Henrik Schroeder, Cormac Owens, Ma
Journal of Clinical Oncology.2021; : JCO.20.03144.     CrossRef
Association of PARP1 polymorphisms with response to chemotherapy in patients with high‐risk neuroblastoma
Marianna Avitabile, Vito Alessandro Lasorsa, Sueva Cantalupo, Antonella Cardinale, Flora Cimmino, Annalaura Montella, Dalila Capasso, Riccardo Haupt, Loredana Amoroso, Alberto Garaventa, Alessandro Quattrone, Maria Valeria Corrias, Achille Iolascon, Mario
Journal of Cellular and Molecular Medicine.2020; 24(7): 4072.     CrossRef
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
Ladenstein, Pötschger, Valteau-Couanet, Luksch, Castel, Ash, Laureys, Brock, Michon, Owens, Trahair, Chi Fung Chan, Ruud, Schroeder, Beck-Popovic, Schreier, Loibner, Ambros, Holmes, Castellani, Gaze, Garaventa, Pearson, Lode
Cancers.2020; 12(2): 309.     CrossRef
Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR
F. Berthold, A. Faldum, A. Ernst, J. Boos, D. Dilloo, A. Eggert, M. Fischer, M. Frühwald, G. Henze, T. Klingebiel, C. Kratz, B. Kremens, B. Krug, I. Leuschner, M. Schmidt, R. Schmidt, R. Schumacher-Kuckelkorn, D. von Schweinitz, F.H. Schilling, J. Theisse
Annals of Oncology.2020; 31(3): 422.     CrossRef
Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma
S. L. George, V. Parmar, F. Lorenzi, L. V. Marshall, Y. Jamin, E. Poon, P. Angelini, L. Chesler
Journal of Experimental & Clinical Cancer Research.2020;[Epub]     CrossRef
Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study
Keith Holmes, Ulrike Pötschger, Andrew D. J. Pearson, Sabine Sarnacki, Giovanni Cecchetto, Javier Gomez-Chacon, Roly Squire, Enrique Freud, Adam Bysiek, Lucas E. Matthyssens, Martin Metzelder, Tom Monclair, Jakob Stenman, Michal Rygl, Lars Rasmussen, Jean
Journal of Clinical Oncology.2020; 38(25): 2902.     CrossRef
Development of differentiation modulators and targeted agents for treating neuroblastoma
Zegao Jin, Yang Lu, Yizhe Wu, Jinxin Che, Xiaowu Dong
European Journal of Medicinal Chemistry.2020; 207: 112818.     CrossRef
A promoter-driven assay for INSM1-associated signaling pathway in neuroblastoma
Chiachen Chen, Michael S. Lan
Cellular Signalling.2020; 76: 109785.     CrossRef
Evolving treatments in high-risk neuroblastoma
Abhinav Kumar, John P J Rocke, B Nirmal Kumar
Expert Opinion on Orphan Drugs.2020; 8(12): 497.     CrossRef
Drug Targeting the Actin Cytoskeleton Potentiates the Cytotoxicity of Low Dose Vincristine by Abrogating Actin-Mediated Repair of Spindle Defects
Yao Wang, Jeffrey H. Stear, Ashleigh Swain, Xing Xu, Nicole S. Bryce, Michael Carnell, Irina B. Alieva, Vera B. Dugina, Timothy P. Cripe, Justine Stehn, Edna C. Hardeman, Peter W. Gunning
Molecular Cancer Research.2020; 18(7): 1074.     CrossRef
Cardiac MRI: a Promising Diagnostic Tool to Detect Cancer Therapeutics–Related Cardiac Dysfunction
Jasmin D. Haslbauer, Sarah Lindner, Gesine Bug, Eike Nagel, Valentina O. Puntmann
Current Cardiovascular Imaging Reports.2019;[Epub]     CrossRef
Therapy intensification in high-risk neuroblastoma patients with poor response to standard induction: experience of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
T. V. Shamanskaya, D. Y. Kachanov, A. V. Dumacheva, M. V. Teleshova, D. V. Shevtcov, T. V. Sergeeva, A. M. Syleimanova, R. A. Moiseenko, Y. N. Likar, . Kailash, S. R. Varfolomeeva
Pediatric Hematology/Oncology and Immunopathology.2019; 18(4): 19.     CrossRef
Molecular mechanisms and therapeutic targets in neuroblastoma
John Inge Johnsen, Cecilia Dyberg, Susanne Fransson, Malin Wickström
Pharmacological Research.2018; 131: 164.     CrossRef
Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma
Fabio Morandi, Loredana Amoroso, Alessandra Dondero, Roberta Castriconi, Stefano Parodi, Roberto Luksch, Fiorina Casale, Aurora Castellano, Alberto Garaventa, Alessandro Moretta, Cristina Bottino, Mirco Ponzoni, Maria Valeria Corrias
OncoImmunology.2018; 7(9): e1468953.     CrossRef
Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma
Joshua Felgenhauer, Laura Tomino, Julia Selich-Anderson, Emily Bopp, Nilay Shah
Neoplasia.2018; 20(10): 965.     CrossRef
Prise en charge des neuroblastomes de haut risque : l’expérience du groupe européen SIOPEN
Dominique Valteau-Couanet, Gudrun Schleiermacher, Sabine Sarnacki, Claudia Pasqualini
Bulletin du Cancer.2018; 105(10): 918.     CrossRef
Novel Therapies for Relapsed and Refractory Neuroblastoma
Peter Zage
Children.2018; 5(11): 148.     CrossRef
Investigational drugs in phase II clinical trials for the treatment of neuroblastoma
Loredana Amoroso, Riccardo Haupt, Alberto Garaventa, Mirco Ponzoni
Expert Opinion on Investigational Drugs.2017; 26(11): 1281.     CrossRef